Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT04750954 |
Title | Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | National Cancer Institute (NCI) |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | United States | Details | |
University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami | Florida | 33136 | United States | Details | |
University of Kentucky/Markey Cancer Center | Lexington | Kentucky | 40536 | United States | Details | |
Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | United States | Details | |
Huntsman Cancer Institute/University of Utah | Salt Lake City | Utah | 84112 | United States | Details |